People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celladon Corp | — | Biotechnology | Series B | $70.9M | $119.1M | 2016 |
| Ocera Therapeutics, Inc. | — | Pharmaceuticals | Series B | $50.0M | $952.1M | 2013 |
| Trius Therapeutics Inc | — | Biotechnology | Series B | $49.3M | $1.2B | 2011 |
| Labrys Biologics, Inc. | — | Pharmaceuticals | Series A | $14.6M | $451.8M | 2012 |
Nina S. Kjellson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nina S. Kjellson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael F. Powell | 2 | 6 |
| Asish Xavier | 1 | 18 |
| Wende Hutton | 1 | 16 |
| Corey Goodman | 1 | 13 |
| Risa Stack | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| David Kabakoff | 1 | 7 |
| Edgar G Engleman | 1 | 5 |
| John Finn | 1 | 5 |
| John Schmid | 1 | 4 |
| Eckard F. Weber | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| Lars G. Ekman | 1 | 3 |
| Krisztina Zsebo | 1 | 3 |
| Brenda D Gavin | 1 | 3 |
| Paul Truex | 1 | 3 |
| Andrew E. Senyei | 1 | 3 |
| James H. Welch | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.